Titre
Stereotactic arrhythmia radioablation: A multicenter pre-post intervention safety evaluation of the implantable cardioverter-defibrillator function.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
van der Ree, M.H.
Auteure/Auteur
Hoeksema, W.F.
Auteure/Auteur
Luca, A.
Auteure/Auteur
Visser, J.
Auteure/Auteur
Balgobind, B.V.
Auteure/Auteur
Zumbrink, M.
Auteure/Auteur
Spier, R.
Auteure/Auteur
Herrera-Siklody, C.
Auteure/Auteur
Lee, J.
Auteure/Auteur
Bates, M.
Auteure/Auteur
Daniel, J.
Auteure/Auteur
Peedell, C.
Auteure/Auteur
Boda-Heggemann, J.
Auteure/Auteur
Rudic, B.
Auteure/Auteur
Merten, R.
Auteure/Auteur
Dieleman, E.M.
Auteure/Auteur
Rinaldi, C.A.
Auteure/Auteur
Ahmad, S.
Auteure/Auteur
Whitaker, J.
Auteure/Auteur
Bhagirath, P.
Auteure/Auteur
Hatton, M.Q.
Auteure/Auteur
Riley, S.
Auteure/Auteur
Grehn, M.
Auteure/Auteur
Schiappacasse, L.
Auteure/Auteur
Blanck, O.
Auteure/Auteur
Hohmann, S.
Auteure/Auteur
Pruvot, E.
Auteure/Auteur
Postema, P.G.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1879-0887
Statut éditorial
Publié
Date de publication
2023-09-12
Volume
189
Première page
109910
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Stereotactic arrhythmia radioablation (STAR) appears to be beneficial in selected patients with therapy-refractory ventricular tachycardia (VT). However, high-dose radiotherapy used for STAR-treatment may affect functioning of the patients' implantable cardioverter defibrillator (ICD) by direct effects of radiation on ICD components or cardiac tissue. Currently, the effect of STAR on ICD functioning remains unknown.
A retrospective pre-post multicenter study evaluating ICD functioning in the 12-month before and after STAR was performed. Patients with (non)ischemic cardiomyopathies with therapy-refractory VT and ICD who underwent STAR were included and the occurrence of ICD-related adverse events was collected. Evaluated ICD parameters included sensing, capture threshold and impedance. A linear mixed-effects model was used to investigate the association between STAR, radiotherapy dose and changes in lead parameters over time.
In total, 43 patients (88% male) were included in this study. All patients had an ICD with an additional right atrial lead in 34 (79%) and a ventricular lead in 17 (40%) patients. Median ICD-generator dose was 0.1 Gy and lead tip dose ranged from 0-32 Gy. In one patient (2%), a reset occurred during treatment, but otherwise, STAR and radiotherapy dose were not associated with clinically relevant alterations in ICD leads parameters.
STAR treatment did not result in major ICD malfunction. Only one radiotherapy related adverse event occurred during the study follow-up without patient harm. No clinically relevant alterations in ICD functioning were observed after STAR in any of the leads. With the reported doses STAR appears to be safe.
A retrospective pre-post multicenter study evaluating ICD functioning in the 12-month before and after STAR was performed. Patients with (non)ischemic cardiomyopathies with therapy-refractory VT and ICD who underwent STAR were included and the occurrence of ICD-related adverse events was collected. Evaluated ICD parameters included sensing, capture threshold and impedance. A linear mixed-effects model was used to investigate the association between STAR, radiotherapy dose and changes in lead parameters over time.
In total, 43 patients (88% male) were included in this study. All patients had an ICD with an additional right atrial lead in 34 (79%) and a ventricular lead in 17 (40%) patients. Median ICD-generator dose was 0.1 Gy and lead tip dose ranged from 0-32 Gy. In one patient (2%), a reset occurred during treatment, but otherwise, STAR and radiotherapy dose were not associated with clinically relevant alterations in ICD leads parameters.
STAR treatment did not result in major ICD malfunction. Only one radiotherapy related adverse event occurred during the study follow-up without patient harm. No clinically relevant alterations in ICD functioning were observed after STAR in any of the leads. With the reported doses STAR appears to be safe.
PID Serval
serval:BIB_E3F5CBDEA9BF
PMID
Open Access
Oui
Date de création
2023-09-20T10:59:07.727Z
Date de création dans IRIS
2025-05-21T05:58:29Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
37709052.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
2.32 MB
Format
Adobe PDF
PID Serval
serval:BIB_E3F5CBDEA9BF.P001
URN
urn:nbn:ch:serval-BIB_E3F5CBDEA9BF8
Somme de contrôle
(MD5):b439527e66fa1d0119b44ab740a03cdd